Antiangiogenic effects of zoledronate on cancer neovasculature.

Metcalf, S, Pandha, HS and Morgan, R (2011) Antiangiogenic effects of zoledronate on cancer neovasculature. Future Oncol, 7 (11). pp. 1325-1333.

	Text ZA_review HP 200911.doc Restricted to Repository staff only Download (297kB)
	Text table1.doc Restricted to Repository staff only Download (34kB)
	Text table 2.doc Restricted to Repository staff only Download (60kB)
	Text table 3.doc Restricted to Repository staff only Download (34kB)

Abstract

Angiogenesis, one of the hallmarks of cancer, supplies nutrients to cancerous tissues to facilitate rapid growth. Targeting cancer-associated angiogenesis is an important goal in cancer therapy and there are currently many drugs that affect tumor-associated vasculature. In this article, we will focus on the antiangiogenic effects of zoledronate (ZA), a bisphosphonate drug routinely used in the treatment of cancer-associated bone disease. This article covers the known effects of ZA throughout the clinical process. It also covers the animal models of cancer that have been treated with ZA and evaluated for angiogenes is, concluding with the current clinical data pertaining to angiogenic factors after ZA treatment.

Item Type:	Article
Divisions :	Surrey research (other units)
Authors :	Metcalf, S, Pandha, HS and Morgan, R
Date :	November 2011
DOI :	10.2217/fon.11.113
Depositing User :	Symplectic Elements
Date Deposited :	28 Mar 2017 14:39
Last Modified :	24 Jan 2020 11:36
URI:	http://epubs.surrey.ac.uk/id/eprint/227184

Actions (login required)

View Item

Downloads